CD19/CD22 CAR-T

DRUG2 trials

Sponsors

Federal Research Institute of Pediatric Hematology, Oncology and Immunology, The First Affiliated Hospital of Soochow University

Conditions

B-ALLRelapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase 1

Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL

Active, not recruitingNCT04499573

Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyB-ALL

Start: 2020-07-27End: 2027-03-13Target: 50Updated: 2023-02-22

Unknown Phase

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

The First Affiliated Hospital of Soochow UniversityRelapsed or Refractory B-cell Non-Hodgkin Lymphoma

Start: 2022-07-01End: 2024-06-30Target: 20Updated: 2023-04-04